-
Dorsomorphin 2HCl: AMPK Workflow Guide
2026-09-01
Dorsomorphin 2HCl is a practical AMPK inhibitor for testing whether metabolic phenotypes are pathway-dependent, but its BMP activity makes experimental controls essential. This guide translates an alcohol-induced hepatic steatosis study into reproducible cell, animal, formulation, and troubleshooting workflows.
-
CX-5461, DNA Damage, and Mitotic Catastrophe
2026-09-01
A June 2026 Biochemical Pharmacology study shows that CX-5461, a selective RNA polymerase I inhibitor, suppresses cervical cancer cell growth by coupling DNA damage to aberrant mitotic entry and mitotic catastrophe. The work also identifies enhanced cisplatin sensitivity, providing a mechanistic rationale for investigating Pol I inhibition in recurrent or platinum-resistant cervical cancer models.
-
ETS1–SENP2–HSPA8/FUNDC1 Axis in BPD
2026-08-31
A 2026 study identifies ETS1 as an upstream regulator of mitochondrial quality control in hyperoxia-induced bronchopulmonary dysplasia. Its mechanistic model links ETS1-driven SENP2 transcription to FUNDC1 deSUMOylation, HSPA8-dependent FUNDC1 turnover, and suppression of excessive mitophagy, providing a framework for studying mitochondrial damage in developing lung tissue.
-
Pam3CSK4 TFA: Reliable TLR1/2 Assay Design
2026-08-31
A scenario-driven guide to using Pam3CSK4 TFA (SKU B5662) for controlled TLR1/2 stimulation, cytokine profiling, and interpretation of viability or cytotoxicity data. It covers assay compatibility, formulation, storage, data analysis, and practical supplier-selection criteria.
-
Polybrene for Viral Delivery and p53 Assays
2026-08-30
Polybrene (Hexadimethrine Bromide) 10 mg/mL helps researchers improve lentiviral, retroviral, and selected lipid-mediated DNA delivery workflows. Its value extends beyond transduction: it can support controlled mutant-p53 model construction while enabling cleaner downstream assays of TRAP-1-driven transcriptional reactivation.
-
25-Hydroxycholesterol Reprograms TAM Immunity
2026-08-29
The reference study identifies CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that links lysosomal lipid handling to AMPK–STAT6 signaling and ARG1 production in tumor-associated macrophages. Its findings suggest that targeting this axis can increase T-cell activity and improve anti-PD-1 responses, while also providing a framework for comparing macrophage lipid metabolism with other tumor-metabolic perturbations.
-
Pterostilbene and Mitochondrial Quality in Fibroblasts
2026-08-28
Zhou et al. show that pterostilbene limits senescence in human dermal fibroblasts by improving mitochondrial morphology, membrane potential, respiration, and mitophagy across both UVB-induced and replicative models. The study supports mitochondrial quality control as a mechanistic target in dermal aging, while also defining practical assay combinations for evaluating senescence and extracellular matrix preservation.
-
HMGCS2 Links LysoPC to Pulmonary Fibrosis
2026-08-28
Yang et al. identify injured alveolar type II epithelial cells as a major source of accumulated LysoPCs and show that these lipids activate lung fibroblasts during experimental pulmonary fibrosis. Their integrated lipidomic, transcriptomic, genetic, and animal-model data connect reduced epithelial HMGCS2 with impaired lipid degradation through a PPARα–CPT1A/CPT2 pathway.
-
Resazurin Cell Viability Assay Kit for Wnt Studies
2026-08-27
Use a sensitive, non-toxic redox readout to separate Wnt-driven changes in osteoblast activity from treatment-related cell loss. The Resazurin Cell Viability Assay Kit adds a rapid fluorescence or colorimetric checkpoint to LGK974 experiments, dose-response studies, and high-throughput screening workflows.
-
GTP Solution: From Stock Integrity to RNA Evidence
2026-08-27
GTP Solution (100 mM) supports controlled nucleotide handling from in vitro transcription through localized p21 mRNA research. This article presents an assay-centered framework for connecting GTP quality, RNA characterization, lipid nanoparticle delivery, and biologically interpretable bladder cancer endpoints.
-
Meropenem Trihydrate and the Next AMR Decision Layer
2026-08-26
Meropenem trihydrate is more than a broad-spectrum carbapenem antibiotic: it can serve as a mechanistic probe for linking cell-wall stress, resistance phenotypes, and metabolomic signatures. This thought-leadership article outlines how translational researchers can integrate the compound into resistance profiling, infection-model validation, and carefully bounded preclinical studies.
-
Cefodizime: From PBP Biology to Resistance Strategy
2026-08-26
A translational perspective on Cefodizime that connects PBP-targeted bactericidal activity, susceptibility testing, immunomodulatory biology, pharmacokinetic context, and antimicrobial stewardship.
-
FerroOrange for Live-Cell Fe²⁺ Detection
2026-08-25
FerroOrange is a live-cell Fe²⁺ fluorescent probe for connecting labile ferrous iron signals with neuronal injury, microglial activation, and ferroptosis workflows. This practical guide covers imaging, flow cytometry, plate-based assays, protocol design, and troubleshooting around the Cdk5–AMPK stroke study.
-
Asunaprevir (BMS-650032) HCV Assay Guide
2026-08-25
Asunaprevir (BMS-650032) combines nanomolar NS3/4A protease inhibition with activity across diverse HCV subtypes, making it useful for biochemical, replicon, and cell-based antiviral workflows. This guide explains how to handle the water-insoluble compound, connect protease inhibition to HCV RNA replication inhibition, and troubleshoot assay results without overinterpreting cross-domain oncology evidence.
-
5-Methyl-CTP: An Assay-to-Vaccine Design Guide
2026-08-24
Discover how 5-Methyl-CTP can be evaluated as a controllable variable in mRNA synthesis with modified nucleotides. This guide connects transcript-level quality assays with translational lessons from an H5N1 mRNA vaccine study in dairy cattle.